| Name | Voltage-dependent anion-selective channel protein 2 | ||
| UniProt ID | VDAC2_HUMAN | ||
| Gene Name | VDAC2 | ||
| Gene ID | 7417 | ||
| Synonyms |
VDAC2, POR
|
||
| Sequence |
MATHGQTCARPMCIPPSYADLGKAARDIFNKGFGFGLVKLDVKTKSCSGVEFSTSGSSNT
DTGKVTGTLETKYKWCEYGLTFTEKWNTDNTLGTEIAIEDQICQGLKLTFDTTFSPNTGK KSGKIKSSYKRECINLGCDVDFDFAGPAIHGSAVFGYEGWLAGYQMTFDSAKSKLTRNNF AVGYRTGDFQLHTNVNDGTEFGGSIYQKVCEDLDTSVNLAWTSGTNCTRFGIAAKYQLDP TASISAKVNNSSLIGVGYTQTLRPGVKLTLSALVDGKSINAGGHKVGLALELEA |
||
| Pathway Map | MAP LINK | ||
| T.C. Number | 1.B.8.1.12 | ||
| KEGG ID | hsa7417 | ||
| TTD ID | T35158 | ||
| Pfam | PF01459 | ||
| Pair Name | Bisdemethoxycucurmin, Icotinib | |||
| Phytochemical | Bisdemethoxycucurmin | |||
| Drug | Icotinib | |||
| Disease Info | [ICD-11: 2C25] | Lung cancer | Investigative | |
| Regulate Info | Down-regulation | Voltage-dependent anion-selective channel protein 2 | Expression | |
| Result | Our data indicate that BMDC has the potential to improve the treatment of primary EGFR-TKI resistant NISCLC that cannot be controlled with single-target agent, such as icotinib. | |||
